Recently, HER2 was selected as a target and anti-HER2 affibody expressed on the surface of OMVs was used for cancer-specific targeting due to its very high affinity and small size (Gujrati et al., 2014), which led us to design our engineered OMVs toward triple-negative breast cancer. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.